• Received the commendation for promoting the 3R (Reduce, Reuse, Recycle) in the 6th year of Reiwa era.
• Recognition for efforts to separate plastics and aluminum from domestic first PTP packaging waste material, contributing to the promotion of recycling activities.
• Aiming to expand initiatives for the entire domestic pharmaceutical industry and the global manufacturing network within the company, promoting activities.

We are pleased to announce that we have received the 'Minister of Health, Labour and Welfare Award' in the Reiwa 6th year Reduce, Reuse, Recycle Promotion Achievement Awards.

This award recognizes our efforts at the Mits factory, our major domestic production site, to separate different materials, aluminum and plastics, from PTP packaging waste for the first time in Japan, leading to considerations for their recycling.

At the Mits factory, approximately half of the industrial waste discharged as plastics consists of 'PTP packaging waste material', a significant project for the company. Considering the reduction of greenhouse gas emissions in the healthcare ecosystem as an urgent issue, we are actively sharing necessary information and promoting the adoption of this method by other industry peers.

In addition, in the transportation from the factory to the waste intermediate treatment contractor, we are making a modal shift to railroad transportation, which has less environmental impact among various transport methods, instead of truck transportation in most of the transportation routes, in order to reduce CO2 emissions.

Takeda's Global Manufacturing & Supply Japan Head, Yukohiro Matsumoto, stated, "I am delighted to receive this award. This award reaffirms the value of our commitment to reduce environmental impact through pharmaceutical manufacturing and contribute to the conservation of the natural environment for nurturing life on Earth. As evident from the principles of a circular economy, we believe there is a crucial connection between people's health and the Earth's environment. We will continue to expand these efforts to the entire industry and our global network to work towards a sustainable future for all people."

The company aims to achieve net zero greenhouse gas emissions throughout the entire value chain by 2040. Takeda's greenhouse gas emission target for 2024 has been certified by the Science Based Targets initiative (SBTi) to align with emission levels needed to limit the global temperature rise to 1.5 degrees Celsius since pre-Industrial Revolution. The goal for reducing landfill waste is to achieve a 90% reduction worldwide by 2030.

This award, initiated by the Reduce, Reuse, Recycle Promotion Council since 1991 with the aim of promoting the formation of a circular society, is awarded to individuals, schools, organizations, etc., who have taken a leading role in the 3Rs activities of waste reduction, reuse, and recycling, and have achieved remarkable results.

New technology overview of 'separation' (outsourced equipment): PTP waste is input into a dedicated device where plastic and aluminum are separated by stirring and friction without combustion. This device operates on electricity but utilizes 100% renewable energy.
Refer to the Ministry of Land, Infrastructure, Transport, and Tourism for details on 'Modal Shift'.
Reduce, Reuse, Recycle Promotion Council
The council is dedicated to promoting a national movement by collaborating with various stakeholders such as consumers, educational institutions, industries, and government agencies to advance the 3R initiatives throughout Japan.

Here is the English version of the press release
Please use your Futubull account to access the feature.

About Takeda Pharmaceutical

Takeda Pharmaceutical Industries, Ltd. (TSE: 4502/NYSE: TAK) aims to contribute to the health and a brighter future of people around the world. We are working to create innovative pharmaceutical products in major disease areas and business fields such as digestive system and inflammatory diseases, rare diseases, plasma fractionation products, neuroscience (neuropsychiatric disorders), oncology (cancer), and vaccines. Together with our partners, we are working to deliver new treatment options by building a strong and diverse pipeline, and to improve the quality of life of patients. Takeda Pharmaceutical is a research and development-based leading company of bio-pharmaceuticals with its headquarters in Japan, which is rooted in the value (values) of patient-centeredness based on its corporate philosophy. Based on the values ​​that have been formed for over 2 centuries, we are working in about 80 countries and regions to fulfill our purpose in society. Please see the website for more details.
Please refer to the website for details.

Kumi Iiyama
080-5789-7742
[email protected]